Description:
ChromogenixCoatest®APC™Resistance–VisanAPTT-basedassaykitforthescreeningoffactor-V-relatedAPCresistance.ThehighsensitivityandspecificityofthetestforthefactorV:Q506mutationisobtainedbypredilutingthesampleplasmawithanexcessofV-DEFPlasmabioreagent.ThetestdesignmakesitpossIBLetodiscriminatebetweenheterozygousandhomozygousfactorVgenotypes.Italsoallowsforanalysisofplasmafrompatientsonheparinororalanticoagulanttherapy.Highdiscriminationbetweengenotypeswith100%sensitivityforFV:Q506.ReducesneedforPCRdetermination.Applicabletoanticoagulanttreatedpatients.
Atime-andmoney-savingalternativetoindividualgenetictesting,Coatest©APC™Resistancetestingisanidealsolutionforphysiciansandlabs.Eachkitwasdesignedtobeeasytouseforin-housescreening,offeringfastresultsandlowcostsforbothlarge-andsmall-volumelabs.ThemostcommonFVLeidenscreeningtestperformed,itoffersunmatchedsensitivityfortheFV:Q506mutation–closeto100%specificity–andisapplicabletopatientsonheparinorwarfarin.
MeasurementPrinciple:
OnevolumeofplasmaispredilutedwithfourvolumesofV-DEFPlasma.ThedilutionisthenincubatedwiththeAPTTreagentforastandardperiodoftime.CoagulationistriggeredbytheadditionofCaCl2intheabsenceandpresenceofexogenousAPCandthetimeforclotformationisrecorded.
ActivatedProteinC(APC)isaregulatorofthecoagulationcascade,byspecificallyinactivatingfactorsVaandVIIIa,inthepresenceofphospholipidsandcalcium. Inmostofthecases(morethan90%),ActivatedProteinCResistance(APCR)phenotypeiscausedbyaFactorVgenemutation(FactorVLeiden).Themutation,locatedonFactorVexon10(1691G–>A),ofargininetoglutamineonposition506,rendersFactorVaresistanttothecleavagebyActivatedProteinC.ThisgeneticanomalycanbeevidencedwithaclottingmethodperformedinthepresenceortheabsenceofActivatedProteinC.
KitComposition:
ReagentsandtheirstABIlitywhenopened
| Reagent | Size | Stability | Temp |
| APC/CaCl2 | 4×2ml | 5days 8hours | 2-8°C 15-25°C |
| APTTreagent | 1×16ml | 1week 1month | 15-25°C 2-8°C |
| CaCl2 | 1×8ml | 1month 1week | 2-8°C 15-25°C |
| V-DEFPlasma | 4×4ml | 8hours 24hours 3months | 15-25°C 2-8°C -20°C |
| APC/CaCl2 | 4×2ml | 3months | -20°C |
| ControlPlasmaLevel1 | 1×1ml | 6hours 3months | 2-25°C -20°C |
| ControlPlasmaLevel2 | 1×1ml | 6hours 3months | 2-25°C -20°C |
Determinationsperkit:80–160
FactorVLeidenTestingAlgorithm:
IDEALFOR:
- Labslookingtobringtestingin-house
- Labslookingforcostsavings
- Orderingphysicianslookingforasensitiveassaywithrapidturnaround
- Savesthelabfromhavingtoperformgenetictestonallpatients
- Economicalalternativetogenetictesting
FV:Q506MutationScreening:
TheChromogenixCoatestAPCResistanceVmethodwasusedforanalysisofplasmafromvarioussamplecategoriesshowingdiscriminationbetweennormalandmutatedfactorVgenotypes.
OAC=OralAnticoagulantTherapy
Background:
ActivatedProteinC(APC)isaregulatorofthecoagulationcascade,byspecificallyinactivatingfactorsVaandVIIIa,inthepresenceofphospholipidsandcalcium.
Inmostofthecases(morethan90%),ActivatedProteinCResistance(APCR)phenotypeiscausedbyaFactorVgenemutation(FactorVLeiden).Themutation,locatedonFactorVexon10(1691G–>A),ofargininetoglutamineonposition506,rendersFactorVaresistanttothecleavagebyActivatedProteinC.ThisgeneticanomalycanbeevidencedwithaclottingmethodperformedinthepresenceortheabsenceofActivatedProteinC.
ActivatedProteinCResistanceistestedbyusingaclottingmethodperformedwithorwithoutActivatedProteinC.
Readmore…
